Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 12/11/2019
SIETES contiene 92833 citas

 1 a 20 de 23 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Troubles rétiniens d'origine médicamenteuse. Prescrire 2019;39:19-25. [Ref.ID 103005]
2. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
3. Cita con resumen
Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]
4. Cita con resumen
Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364:535-41. [Ref.ID 90172]
5. Cita con resumen
Naughton C. Drug-induced nephrotoxcicity. American Family Physician 2008;78:743-50. [Ref.ID 87065]
Anónimo. Les pneumopathies interstitielles dues à des médicaments. Prescrire 2007;27:510-2. [Ref.ID 80442]
7. Cita con resumen
Bradbury J. Beyond pills and jabs. Lancet 2003;362:1984-5. [Ref.ID 68468]
8. Cita con resumen
Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Müller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V, for the German Hodgkin's Lymphoma Study Group (GHSG) and the Lymphoma Working Party of the European for Blood and Marrow Transplantation (EBMT). Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-71. [Ref.ID 62646]
Kintzel PE. Anticancer drug-induced kidney disorders: incidence, prevention and management. Drug Saf 2001;24:19-38. [Ref.ID 59615]
10.Tiene citas relacionadas
Herold M. Bendamustine: viewpoint. Drugs 2001;61:640. [Ref.ID 56412]
11.Tiene citas relacionadas
Schöffski P, Ganser A. Bendamustine: viewpoint. Drugs 2001;61:639. [Ref.ID 56411]
12.Tiene citas relacionadas Cita con resumen
Barman Balfour JA, Goa KL. Bendamustine. Drugs 2001;61:631-8. [Ref.ID 56410]
Shen J, Wenger N, Glaspy J, Hays RD, Albert PS, Choi C, Shekelle PG. Electroacupuncture for control of myeloablative chemotherapy-induced emesis. A randomized controlled trial. JAMA 2000;284:2755-61. [Ref.ID 54464]
14.Tiene citas relacionadas Cita con resumen
Weinstein JN. Pharmacogenomics - teaching old drugs new tricks. N Engl J Med 2000;343:1408-9. [Ref.ID 53960]
15.Tiene citas relacionadas Cita con resumen
Esteller M, García-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4. [Ref.ID 53958]
16. Cita con resumen
Anónimo. Drugs of choice for cancer chemotherapy. Med Lett Drugs Ther 2000;42:83-92. [Ref.ID 52816]
Pai VP, Nahata M C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263-302. [Ref.ID 50164]
Durán García E, Santolaya R, Requena T. Treatment of malignant melanoma. Ann Pharmacother 1999;33:730-8. [Ref.ID 45095]
Huang YW, Hamilton A, Arnuk OJ, Chaftari P, Chemaly R. Current drug therapy for multiple myeloma. Drugs 1999;57:485-506. [Ref.ID 43977]
Seleccionar todas
 1 a 20 de 23 siguiente >>